ArticleNeuropsychiatric disease and treatment2026
Validation and Functional Exploration of Exosome-Derived ITGA9-AS1 and WNT5A-AS1 as Candidate Diagnostic Biomarkers for Schizophrenia.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Schizophrenia lacks objective biomarkers, and its complex aetiology demands epigenetic insight. Given the regulatory roles of long non-coding RNAs (lncRNAs) in the nervous system and brain-relevant signals in peripheral exosomes, we evaluated lncRNA expression in patient blood cells and plasma exosomes, assessed their diagnostic value, and explored potential functions and mechanisms. Methods: Differentially expressed lncRNAs in schizophrenia-related exosomes were identified from GEO (GSE228881), and 15 candidates were selected for validation. In a clinical cohort, RT-qPCR assessed their expression in peripheral blood cells and plasma exosomes. Diagnostic accuracy was evaluated by ROC analysis. Top dysregulated lncRNAs underwent bioinformatic analyses: subcellular localization, evolutionary conservation, ceRNA network construction, and GO/KEGG enrichment. Results: ITGA9-AS1 and WNT5A-AS1 were significantly upregulated in both peripheral blood cells and plasma exosomes from patients. Both showed favorable diagnostic potential, with AUC values of 0.8422 and 0.8073, respectively, in peripheral blood; their combination yielded an AUC of 0.9180. Bioinformatics analysis revealed that ITGA9-AS1 primarily localizes to the cytoplasm, whereas WNT5A-AS1 is enriched in exosomes, with both exhibiting high evolutionary conservation. Functional predictions suggest ITGA9-AS1 may regulate neuroplasticity-related pathways such as "long-term potentiation" and "cAMP signaling pathway" via a ceRNA mechanism. WNT5A-AS1 may mediate intercellular communication through exosomes, influencing developmental and metabolic pathways, including the "Notch signaling pathway" and "cysteine and methionine metabolism". Conclusion: Our findings suggest that ITGA9-AS1 and WNT5A-AS1 are highly promising biomarker candidates for schizophrenia. They may be involved in the disease process through distinct mechanisms (intracellular regulation and intercellular communication), thus providing a new theoretical framework and suggesting potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.